Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Declines By 25.2%

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a significant decrease in short interest in October. As of October 15th, there was short interest totalling 104,800 shares, a decrease of 25.2% from the September 30th total of 140,100 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average trading volume of 148,900 shares, the short-interest ratio is presently 0.7 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xilio Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 295,000 shares of the company’s stock after purchasing an additional 45,554 shares during the period. Renaissance Technologies LLC owned 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent quarter. 54.29% of the stock is owned by hedge funds and other institutional investors.

Xilio Therapeutics Price Performance

Shares of XLO traded up $0.02 during midday trading on Friday, hitting $0.95. The stock had a trading volume of 168,429 shares, compared to its average volume of 528,876. The firm has a market cap of $35.07 million, a price-to-earnings ratio of -0.37 and a beta of -0.10. The company has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.95. Xilio Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.89.

Xilio Therapeutics (NASDAQ:XLO) last announced its earnings results on Thursday, August 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.01). The company had revenue of $2.36 million during the quarter, compared to analyst estimates of $30.00 million. Analysts forecast that Xilio Therapeutics will post -1.26 EPS for the current fiscal year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.